Kura Oncology, Inc.

( )
KURA PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 0.92%286.020.0%$3988.07m
BNTXBioNTech SE 1.39%295.990.0%$1278.94m
NVAXNovavax, Inc. 4.81%190.5078.2%$906.19m
AMGNAmgen, Inc. 0.07%213.681.4%$652.04m
LGVNLongeveron Inc. 0.09%21.920.0%$515.78m
GILDGilead Sciences, Inc. -0.19%69.581.0%$514.17m
VRTXVertex Pharmaceuticals, Inc. 0.09%206.801.9%$454.51m
REGNRegeneron Pharmaceuticals, Inc. 0.00%654.042.7%$419.38m
ILMNIllumina, Inc. -0.05%375.813.3%$351.61m
SNSSSunesis Pharmaceuticals, Inc. 0.00%4.360.7%$304.78m
BIIBBiogen, Inc. -0.01%234.701.8%$297.94m
SGENSeagen Inc. 0.00%149.555.8%$157.99m
EXASEXACT Sciences Corp. 0.00%86.2618.0%$150.95m
INCYIncyte Corp. 0.00%67.332.4%$147.13m
TXG10X Genomics, Inc. 2.17%155.410.0%$140.47m

Company Profile

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.